Publications by authors named "R Fonte"
Introduction: The treatment of glioblastoma is hindered by the blood-brain barrier (BBB) and rapid drug clearance by the immune system. To address these challenges, we propose a novel drug delivery system using liposomes modified with cell membrane fragments. These modified liposomes can evade the immune system, cross the BBB, and accumulate in tumor tissue through homotypic targeting, thereby delivering drugs like paclitaxel and carboplatin more effectively.
View Article and Find Full Text PDFArticle Synopsis
- Radiofrequency ablation (RFA) is a safe treatment for benign thyroid nodules, but it carries a risk of injury to the recurrent laryngeal nerve (RLN), which can affect voice function.
- The study highlights the use of flexible laryngoscopy (FL) to monitor vocal cord (VC) function during RFA, ensuring safety before treating the second nodule in a patient with hyperthyroidism.
- The findings suggest that using FL is an effective way to minimize RLN injury risk during both single and bilateral RFA treatments, even when the patient is awake.
Objective: Radiofrequency ablation (RFA) is an emerging non-surgical treatment for benign thyroid nodules (BTN). Despite its proven safety profile, data on the learning curve (LC) required to achieve proficiency are still lacking.
Materials And Methods: The first 179 RFA procedures performed by a single operator in patients with non-functioning BTN were retrospectively analyzed.
Small-cell lung cancer (SCLC) cases represent approximately 15% of all lung cancer cases, remaining a recalcitrant malignancy with poor survival and few treatment options. In the last few years, the addition of immunotherapy to chemotherapy improved clinical outcomes compared to chemotherapy alone, resulting in the current standard of care for SCLC. However, the advantage of immunotherapy only applies to a few SCLC patients, and predictive biomarkers selection are lacking for SCLC.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on optimizing treatments for metastatic melanoma (MM) by developing cell membrane (CM)-modified nanoparticles (NPs) using microfluidics, which enhance drug delivery and targeting.
- The researchers performed a direct membrane fusion process using synthetic liposomes and CM from MM cell lines, loading these hybrid liposomes with targeted agents like cobimetinib and lenvatinib.
- Results showed that these hybrid liposomes had significantly better targeting and effectiveness against MM cells compared to standard liposomes or free drugs, while demonstrating low toxicity.